Adaptimmune Therapeutics PLC

ADAPY Healthcare Biotechnology

Adaptimmune Therapeutics PLC’s revenue for fiscal 2025 (year ended December 2025) was $5.9 million, down 96.7% from fiscal 2024. In the quarter to June 2025, revenue fell 89.3%, EPS fell 140.7% and free cash flow fell 174.7%, each against the same quarter a year earlier.

0.03 0.00 0.00%
Market cap
$14.6M
P/E
0.0×
Fwd P/E
−0.1×
Dividend yield
—
F-score
4/9
Altman Z
−23.33
Beneish M
16.71
Dividend safety
n/a
Older periods Dec '24 Mar '25 Jun '25 Dec '25
ROE

+8 more TTM periods

(273.57%) 1,087.18% (1,349.52%) —
Piotroski F-Score
4 2 0 —
ROA
(27.17%) (34.11%) (75.53%) 0.00%
ROIC
0.00% 0.00% 0.00% —
Return on Tangible Assets
(46.83%) (86.91%) (311.98%) —
Average Days of Receivables
29.49 8.90 52.23 —
Free Cash Flow per Share
(0.28) (0.41) (0.71) —
Free Cash Flow
(71.02) (105.74) (187.58) —
Other line items

Show all line items

Columns are period end dates